Document:

Addendum to Credit Line Agreement

 Exhibit 10.3 
 Re: Account Number              (the “Account”) 
 ADDENDUM TO CREDIT LINE
AGREEMENT 
 The attached “Credit Line Agreement” sets forth certain terms related to the extension of credit by UBS Bank USA (“The
“Bank”) with respect to certain assets held through the above-referenced non-discretionary corporate cash management Account with UBS Financial Services Inc. (the “Firm”). The party signing this Addendum as Client where indicated
below (the “Client”) understands and agrees that, notwithstanding anything to the contrary contained in either the Credit Line Agreement (including without limitation Section 19 of the Credit Line Agreement) or the existing Corporate Cash
Management Account Agreement applicable to the Account, as amended from time to time (the “Account Agreement”), the terms of the Credit Line Agreement supplement, but do not replace, the existing Account Agreement as follows: (i) the terms
of the Credit Line Agreement (as amended from time to time, in accordance with its terms) shall govern with respect to any matters, issues or disputes related directly to, or arising directly from, the extension of credit and/or the status of Client
as borrower and the Bank as lender pursuant to the Credit Line Agreement (e.g., matters relating to the loan account(s) established at the Bank pursuant to the Credit Line Agreement, and/or the indemnification of the Bank as a lender); and (ii) the
terms of the Account Agreement (as amended from time to time, in accordance with its terms) shall govern with respect to all other matters (e.g., matters relating to the Account established at the Firm pursuant to the Account Agreement, the
Firm’s trading authority and activities and/or the indemnification of the Firm for the services it provides under the Account Agreement). 
 Without
limiting the generality of the foregoing, Client further understands and agrees that: 
 (A) If applicable, Client may continue to receive Financial Advisor
Reports with respect to the Account, from its Financial Advisor that are in addition to the official monthly statements that the Firm provides (“Financial Advisor Reports”). As noted in the disclaimer page for those Financial Advisor
Reports, the Financial Advisor Reports are for informational purposes only and Client should rely on the Firm’s monthly account statements and trade confirmations as the official records relative to the Account. There may be differences between
the Financial Advisor Reports and the Firm’s monthly statements and trade confirmations. The disclaimer page of the Financial Advisor Reports sets forth important terms and conditions applicable to the Financial Advisor Reports. Client’s
receipt of Financial Advisor Reports constitutes Client’s agreement to, and acceptance of, those terms and conditions. 
 (B) Solely with respect to
disputes arising out of the extension of credit and/or the status of Client as borrower and the Bank as lender pursuant to the Credit Line Agreement, the choice of law provisions of Paragraph 13 of the Credit Line Agreement and the dispute
resolution provisions of Section 17 of the Credit Line Agreement shall govern. With respect to any other disputes relating to the Account, the terms of the Account Agreement regarding choice of law and the arbitration of disputes shall continue to
govern. 
 (C) If Client elected or in the future elects to adopt the Firm’s “Addendum Granting Limited Authority to Invest in Money Market Funds
For Non-Discretionary Corporate Cash Management Accounts,” the Firm may continue to exercise the limited discretion described therein with respect to the Account. 
 (D) If Client elected or in the future elects to adopt the “Investment Policy Submission Addendum For Non-Discretionary Corporate Cash Management Accounts,” the terms set forth therein shall continue to
govern with respect to the Account and any investment policy statement associated with the Account. 

 Acknowledged and agreed this 8th day of January, 2009 
  

			
	Client’s Name: Medicinova, Inc.
		
	By:	 	 /s/ Shintaro Asako

		
	Name:	 	Shintaro Asako
		
	Title:	 	Chief Financial Officer/CFOImportant Notice on Interest Rates and Payments

 Exhibit 10.4 
  

			
	

	 	UBS Bank USA
		
		 	

 IMPORTANT NOTICE ON INTEREST RATES AND PAYMENTS 
  

							
	Credit Line Account	  		  	Account Number	  	
	 MEDICINOVA INC
	  		  		  	
				
	 Collateral Account
	  		  	Account Number	  	
	 MEDICINOVA INC
	  		  		  	

 This document contains important information regarding the interest rate and interest payments on your Credit
Line. You should carefully review this Notice and your Credit Line Application and Agreement, including the Addendum, (the “Agreement”) and speak to your Financial Advisor regarding any questions or concerns you may have with your
Agreement. Defined terms used in this Notice have the respective meanings set forth in the Agreement unless defined in this Notice. 
 The Agreement provides
you with a “no net cost” Credit Line. This means that the interest that you pay on the Credit Line Obligations will not exceed the interest that you receive on the Auction Rate Securities that you have pledged to the Bank as security for
the Credit Line and which are held in the Collateral Account. Although you may be able to capitalize interest you will not be charged interest on interest. 
 The Credit Line statements that you receive from the Bank while the Credit Line is outstanding are for information purposes only. The interest charge(s) on these statements are approximations due to timing and systems limitations. You will
receive a final confirmation from the Bank of the interest charged on the Credit Line. This does not change the “no net cost” nature of the Credit Line. 
 If you have Taxable Student Loan Auction Rate Securities pledged as Collateral you may not receive an interest payment in months in which you are charged interest on the Credit Line. Certain taxable student loan ARS made high interest rate
payments to UBSFS investors for several months during the first half of 2008, and then ceased making interest payments in subsequent months. These taxable student loan ARS will not make any further interest payments until a future date determined in
accordance with the terms of the Auction Rate Securities. For the purpose of determining loan interest payments for loans against these Taxable Student Loan Auction Rate Securities, the high interest payments will be taken into consideration (and
the interest rate annualized). For example, you will be charged (i) for the period from the date of the Addendum through and including January 21, 2009, the applicable coupon rate(s) on the Taxable Student Loan Auction Rate Securities and
(ii) from January 22, 2009 and thereafter you will be charged that average annualized rate (e.g., T-bills plus 120 basis points), for each month in which your loan is outstanding, including months for which the annualized interest was paid
in a prior month and for which no additional or current payment is being made to you. 
 Interest on the Credit Line accrues daily and is charged in
accordance with the Bank’s regular interest billing cycle. The Bank’s billing cycle may not be the same as the cycle on which the Auction Rate Securities pay interest. 
 Please acknowledge your receipt and review of this Notice by signing below. 
  

					
	 January 8, 2009
	  	 SHINTARO ASAKO, Chief Financial Officer/CFO
	  	 /s/ Shintaro Asako

	Date	  	Print Name and Title	  	Signature
			
	 January 8, 2009
	  	 YUICHI IWAKI, President and CEO
	  	 /s/ Yuichi Iwaki

	Date	  	Print Name and Title	  	Signature
			
	 January 8, 2009
	  	 MARIE LALAS, Vice-President and Controller
	  	 /s/ Marie Lalas

	Date	  	Print Name and Title	  	Signature
			
		  		  	Date: January 8, 2009

 

 
  

 1 of 1Amendment to Employment Agreement for Thoma R. Wittman dated January 20, 2009

 Exhibit 10.1 
 AMENDMENT TO EMPLOYMENT AGREEMENT 
 This Amendment dated as of January 20, 2009 (this
“Amendment”) to the Employment Agreement dated October 1, 2002 (“Employment Agreement”) is entered into by and between Omega Protein Corporation, a Nevada corporation with headquarters in Houston, Texas (the
“Company”), and Thomas R. Wittmann (the “Employee”). 
 WHEREAS, the Employee has formerly served as the Vice President -
Operations of the Company; and 
 WHEREAS, the Employee and Company desire to change Employee’s responsibilities and base salary; and

 WHEREAS, the Company desires to provide the Employee with certain assurances regarding his employment in the event of termination of
Employee’s employment; and 
 WHEREAS, the Company and Employee desire to make certain amendments to the Employment Agreement;

 THEREFORE, in consideration of the foregoing and the mutual provisions contained herein, and for other good and valuable consideration,
the parties hereto agree with each other as follows: 
 1. Section 1 of the Employment Agreement is hereby amended and restated as
follows: 
 1. Employment. On the terms and subject to the conditions set forth herein, the Company hereby employs the Employee and the
Employee hereby accepts employment with the Company as Director of Manufacturing Services. The Employee will perform the duties, functions and services as the Senior Vice President - Operations of the Company or his designee may from time to time
request. 
 2. Section 2(a) of the Employment Agreement is hereby amended and restated as follows: 
 2. Compensation and Other Employee Benefits. As compensation for the Employee’s services hereunder, the Company will: 
 (a) pay to the Employee an annual base salary (the “Base Salary”), subject to such withholdings or other deductions as may be required by
applicable laws or regulations, of One Hundred Ten Thousand and No/100 Dollars ($110,000.00) effective February 1, 2009 (Employee’s prior salary to remain effective prior to that date) in accordance with the then current payroll policies
of the Company, which Base Salary will be subject to 

  

 1 

 
increase (but not decrease) at the discretion of the Company; and 
 3. Sections 3 (d)i and 3 (d)ii of the Employment Agreement are hereby amended and restated as follows: 
  

	 	(d)	Voluntary Termination by Company. The Company will be entitled to terminate the Employee’s employment at any time for any reason. The severance payment paid to Employee
as a result of voluntary termination by the Company will differ depending on whether such termination takes place before or after a Change of Control (as defined below) has occurred, as set forth below: 

  

	 	(i)	Prior to a Change in Control. If, prior to a Change of Control, the Company terminates the Employee’s employment for any reason other than Due Cause, death or the
Employee’s disability, then the Company will pay to the Employee $159,600 payable in installments pro rata in accordance with the then current payroll policies of the Company over the twelve (12)-month period following such termination, and all
the rights and benefits the Employee may have under any Company health and welfare benefit plans will be determined in accordance with the terms and conditions of those plans. 

  

	 	(ii)	After a Change of Control. If, after a Change of Control, the Company terminates the Employee’s employment within two (2) years after the date of the Change of
Control for any reason other than Due Cause, death or the Employee’s disability, then the Company will pay to the Employee $319,200 payable in installments pro rata in accordance with the then current payroll policies of the Company over the
twenty-four (24)-month period following such termination, and all the rights and benefits the Employee may have under the any health and welfare benefit plan will be determined in accordance with the terms and conditions of those plans.

 4. Section 6(a) and 6(b) is hereby amended and restated as follows: 
 6. Notices. All notices, requests, demands and other communications given under or by reason of this Agreement must be in writing and will be
deemed given when delivered in person or when mailed, by certified mail (return receipt requested), postage prepaid, addressed as follows or to such other address as a party may specify by notice pursuant to this provision: 
  

 2 

					
	(a) If to the Company:	  	 Omega Protein Corporation
 2105 City West Blvd, Suite
500
 Houston, Texas 77042
 Attn: Secretary
	  	
			
	(b) If to the Employee:	  	 Thomas R. Wittmann
 16317 Mayhaw Drive
 Biloxi, MS 39532
	  	

 5. New Section 17 shall be added as follows: 
 17. Section 409A. The Company and Employee agree that this Agreement and Amendment are intended to comply with the requirements of
Section 409A (“Section 409A”) of the Internal Revenue Code of 1986, as amended, and the regulations and other guidance promulgated thereunder (the “Code”) or an exemption from Section 409A and, accordingly, this
Agreement and Amendment shall be interpreted to be consistent with Section 409A. In the event that, as of the date of Employee’s “separation from service,” as defined in Treasury Regulation Section 1.409A-1(h), Employee
is a “specified employee,” as defined in Treasury Regulation Section 1.409A-1(i), to the extent that any of the payments under this Agreement and Amendment payable on account of a separation from service, including without limitation,
any payments in Sections 3d(i) and (ii) are deferred compensation subject to, and not exempt from, Code Section 409A, such amounts shall be paid not earlier than six (6) months after the date of the Employee’s separation from
service within the meaning of Code Section 409A (“Waiting Period”); any payments withheld during the Waiting Period will be paid in a lump sum amount on the first business day of the seventh month following the Employee’s
separation from service and payments thereafter shall be otherwise paid as provided herein. For the purposes of Code Section 409A, to the extent any payment under this Agreement and Amendment is deferred compensation subject to and not
exempt from Code Section 409A, the Employee’s termination from the Company shall mean a separation from service within the meaning of Code Section 409A. 
 6. All other provisions of the Employment Agreement remain unaffected and in full force and effect. 
  

 3 

 IN WITNESS WHEREOF, the Employee and the Company have executed this Agreement effective as of the date
first written above. 
  

			
	OMEGA PROTEIN CORPORATION
		
	By:	 	/s/ John D. Held
		 	John D. Held
		 	Executive Vice President

  

	
	EMPLOYEE
	
	/s/ Thomas R. Wittmann
	Thomas R. Wittmann

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]